Topical acne drugs: Review of clinical properties, systemic exposure, and safety

American Journal of Clinical Dermatology

Volumn 4, Issue 7, 2003, Pages 473-492

  Akhavan, Arash ^a   Bershad, Susan ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADAPALENE; ANTICOAGULANT AGENT; ANTIINFECTIVE AGENT; AZELAIC ACID; BENZACLIN; BENZOYL PEROXIDE; CIMETIDINE; CLINDAMYCIN; CLINDAMYCIN PLUS RETINOIC ACID; CORTICOSTEROID; CYCLOSPORIN; DIGOXIN; DIHYDROERGOTAMINE; DILTIAZEM; DUAC; ERGOTAMINE; ERYTHROMYCIN; ISOTRETINOIN; ISOTREXIN; KERASAL; KETOCONAZOLE; PENTOBARBITAL; PHENOBARBITAL; RETIN A MICRO; RETINOIC ACID; RIFAMPICIN; SALICYLIC ACID; SULFACETAMIDE; SULFUR; TAZAROTENE; TETRACYCLINE; THEOPHYLLINE; TRIAZOLAM; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL;

ACNE; BIRTH DEFECT; BLEEDING; BRAIN PSEUDOTUMOR; BURNING SENSATION; CLINICAL PRACTICE; CONCENTRATION RESPONSE; CONTACT DERMATITIS; DIARRHEA; DISEASE ASSOCIATION; DRUG EXPOSURE; DRUG SAFETY; DYSPNEA; ENTERITIS; EPIPHYSIS INJURY; ERYTHEMA; FEVER; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERLIPIDEMIA; HYPEROSTOSIS; HYPERSENSITIVITY REACTION; HYPERTRIGLYCERIDEMIA; HYPERTROPHIC PYLORUS STENOSIS; HYPOTENSION; LACTATION; LEUKOPENIA; LIVER TOXICITY; LONG QT SYNDROME; LUNG INFILTRATE; MUSCLE CRAMP; NAUSEA; PERICARDIAL EFFUSION; PLEURA EFFUSION; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; PRURITUS; PSEUDOMEMBRANOUS COLITIS; RESPIRATORY TRACT DISEASE; RETINOL INTOXICATION; REVIEW; SIDE EFFECT; SKIN ABRASION; SKIN ABSORPTION; SKIN DISEASE; SKIN IRRITATION; SYSTEMIC DISEASE; THROMBOCYTOPENIA; VERTIGO; VOMITING; WEIGHT GAIN; XEROSIS;

EID: 0038781251     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200304070-00004     Document Type: Review

References (194)

1. Roberts J. Skin conditions of youths 12-17 years, United States. vital and health statistics: Series 11. Data from the National Health Survey, Data from the health examination survey; no. 157. DHEW publication no. (HRA) 76-1639, 1976
2. Krowchuk DP, Stancin T, Keskinen R. et al. The psychosocial effects of acne on adolescents. Pediatr Dermatol 1991 Dec; 8 (4): 332-8
3. Lucky AW, Biro FM, Huster GA, et al. Acne vulgaris in premenarchal girls: an early sign of puberty associated with rising levels of dehydroepiandrosterone. Arch Dermatol 1994; 130: 308-14
4. Goulden V, Clark SM, Cunliffe WJ. Post-adolescent acne: a review of clinical features. Br J Dermatol 1997 Jan; 136 (1): 66-70
5. Lasek RJ, Chren MM. Acne vulgaris and the quality of life of adult dermatology patients. Arch Dermatol 1998 Apr; 134 (4): 454-8
6. Walton S, Wyatt EH, Cunliffe WJ. Genetic control of sebum excretion and acne: a twin study. Br J Dermatol 1988 Mar; 118 (3): 393-6
7. Imperato-McGinley J, Gautier T, Cai LQ, et al. The androgen control of sebum production: studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity. J Clin Endocrinol Metab 1993 Feb; 76 (2): 524-8
8. Marynick SP, Chakmakjian ZH, McCaffree DL, et al. Androgen excess in cystic acne. N Engl J Med 1983 Apr 28; 308 (17): 981-6
9. Lucky AW, McGuire J, Rosenfield RL, et al. Plasma androgens in women with acne vulgaris. J Invest Dermatol 1983 Jul; 81 (1): 70-4
10. Rasmussen JE. Diet and acne. Int J Dermatol 1977 Jul-Aug; 16 (6): 488-92
11. Fulton Jr JE, Plewig G, Kligman AM. Effect of chocolate on acne vulgaris. JAMA 1969 Dec 15; 210 (11): 2071-4
12. Leyden JJ. Therapy for acne vulgaris. N Engl J Med 1997 Apr 17; 336 (16): 1156-62
13. Webster GF. Inflammatory acne. Int J Dermatol 1990 Jun; 29 (5): 313-7
14. Kersey P, Sussman M, Dahl M. Delayed skin test reactivity to Propionibacterium acnes correlates with severity of inflammation in acne vulgaris. Br J Dermatol 1980 Dec; 103 (6): 651-5
15. Mills Jr OH, Kligman AM. Assay of comedolytic activity in acne patients. Acta Derm Venereol 1983; 63 (1): 68-71
16. Goldstein JA, Comite H, Mescon H, et al. Isotretinoin in the treatment of acne: histologic changes, sebum production, and clinical observations. Arch Dermatol 1982; 118 (8): 555-8
17. Bershad SV. The modern age of acne therapy: a review of current treatment options. Mt Sinai J Med 2001; 68 (4-5): 279-86
18. Sykes Jr NL, Webster GF. Acne: a review of optimum treatment. Drugs 1994; 48 (1): 59-70
19. Kawada A, Aragane Y, Kameyama H, et al. Acne phototherapy with a high-intensity, enhanced, narrow-band, blue light source: an open study and in vitro investigation. J Dermatol Sci 2002; 30 (2): 129-35
20. Paithankar DY, Ross EV, Saleh BA, et al. Acne treatment with a 1,450 nm wavelength laser and cryogen spray cooling. Lasers Surg Med 2002; 31 (2): 106-14
21. Schaefer H. Penetration and percutaneous absorption of topical retinoids: a review. Skin Pharmacol 1993; 6 Suppl. 1: 17-23
22. Physicians' desk reference. 56th ed. Montvale (NJ): Medical Economics Company Inc, 2002
23. Jansen BK, McGann LA, Kachevsky V, et al. The negligible systemic availability of retinoids with multiple and excessive topical application of isotretinoin 0.05% gel (Isotrex) in patients with acne vulgaris. J Am Acad Dermatol 1991; 24 (3): 425-8
24. Rougier A, Dupuis D, Lotte C, et al. The measurement of the stratum corneum reservoir: a predictive method for in vivo percutaneous absorption studies: influence of application time. J Invest Dermatol 1985; 84 (1): 66-8
25. Bershad S, Poulin YP, Berson DS, et al. Topical retinoids in the treatment of acne vulgaris. Cutis 1999 Aug; 64 (2 Suppl.): 8-20
26. Bershad S, Kranjac Singer G, Parente JE, et al. Successful treatment of acne vulgaris using a new method: results of a randomized vehicle-controlled trial of short-contact therapy with 0.1% tazarotene gel. Arch Dermatol 2002; 138 (4): 481-9
27. Rougier A, Lotte C, Maibach HI. In vivo percutaneous penetration of some organic compounds related to anatomic site in humans: predictive assessment by the stripping method. J Pharm Sci 1987; 76 (6): 451-4
28. Lotte C, Wester RC, Rougier A, et al. Racial differences in the in vivo percutaneous absorption of some organic compounds: a comparison between black, Caucasian and Asian subjects. Arch Dermatol Res 1993; 284 (8): 456-9
29. Dupuis D, Rougier A, Roguet R, et al. The measurement of the stratum corneum reservoir: a simple method to predict the influence of vehicles on in vivo percutaneous absorption. Br J Dermatol 1986; 115 (2): 233-8
30. Piacquadio D, Kligman A. The critical role of the vehicle to therapeutic efficacy and patient compliance. J Am Acad Dermatol 1998 Aug; 39 (2 Pt 3): S67-73
31. Kligman AM, Fulton Jr JE, Plewig G. Topical vitamin A acid in acne vulgaris. Arch Dermatol 1969; 99 (4): 469-76
32. Sporn MB, Dunlop NM, Newton DL, et al. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 1976; 35 (6): 1332-8
33. Petkovich M, Brand NJ, Krust A, et al. A human retinoic acid receptor which belongs to the family of nuclear receptors. Nature 1987; 330 (6147): 444-50
34. Mangelsdorf DJ, Ong ES, Dyck JA, et al. Nuclear receptor that identifies a novel retinoic acid response pathway. Nature 1990; 345 (6272): 224-9
35. Bershad S. Developments in topical retinoid therapy for acne. Semin Cutan Med Surg 2001; 20 (3): 154-61
36. Weiss JS, Ellis CN, Headington JT, et al. Topical tretinoin improves photoaged skin: a double-blind vehicle-controlled study. JAMA 1988; 259 (4): 527-32
37. Kang S, Leyden JJ, Lowe NJ, et al. Tazarotene cream for the treatment of facial photodamage: a multicenter, investigator-masked, randomized, vehicle-controlled, parallel comparison of 0.01%, 0.025%, 0.05%, and 0.1% tazarotene creams with 0.05% tretinoin emollient cream applied once daily for 24 weeks. Arch Dermatol 2001 Dec; 137 (12): 1597-604
38. Duvic M, Nagpal S, Asano AT, et al. Molecular mechanisms of tazarotene action in psoriasis. J Am Acad Dermatol 1997; 37 (2 Pt 3): S18-24
39. Weinstein GD, Krueger GG, Lowe NJ, et al. Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect. J Am Acad Dermatol 1997; 37 (1): 85-92
40. Walmsley S, Northfelt DW, Melosky B, et al. Treatment of AIDS-related cutaneous Kaposi's sarcoma with topical alitretinoin (9-cis-retinoic acid) gel. Panretin Gel North American Study Group. J Acquir Immune Defic Syndr 1999; 22 (3): 235-46
41. Duvic M, Hymes K, Heald P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001; 19 (9): 2456-71
42. Marcelo CL, Madison KC. Regulation of the expression of epidermal keratinocyte proliferation and differentiation by vitamin A analogs. Arch Dermatol Res 1984; 276 (6): 381-9
43. Stadler R, Muller R, Detmar M, et al. Retinoids and keratinocyte differentiation in vitro. Dermatologica 1987; 175 Suppl. 1: 45-55
44. Lavker RM, Leyden JJ, Thorne EG. An ultrastructural study of the effects of topical tretinoin on microcomedones. Clin Ther 1992; 14 (6): 773-80
45. Roos TC, Jugert FK, Merk HF, et al. Retinoid metabolism in the skin. Pharmacol Rev 1998; 50 (2): 315-33
46. Mills Jr OH, Kligman AM. Treatment of acne vulgaris with topically applied erythromycin and tretinoin. Acta Derm Venereol 1978; 58 (6): 555-7
47. Amblard P, Bazex A, Beylot C, et al. The association tretinoin-erythromycin base: a new topical treatment for acne: results of a multicentric trial on 347 cases (authors transl). Sem Hop 1980; 56 (17-18): 911-5
48. Gould DJ, Ead R, Cunliffe WJ. Oral tetracycline and retinoic acid gel in acne. Practitioner 1978; 221 (1322): 268-71
49. Bucknall JH, Murdoch PN. Comparison of tretinoin solution and benzoyl peroxide lotion in the treatment of acne vulgaris. Curr Med Res Opin 1977; 5 (3): 266-8
50. Swinyer LJ, Swinyer TA, Britt MR. Topical agents alone in acne: a blind assessment study. JAMA 1980; 243 (16): 1640-3
51. Krishnan G. Comparison of two concentrations of tretinoin solution in the topical treatment of acne vulgaris. Practitioner 1976; 216 (1291): 106-9
52. Webster GF, Berson D, Stein LF, et al. Efficacy and tolerability of once-daily tazarotene 0.1% gel versus once-daily tretinoin 0.025% gel in the treatment of facial acne vulgaris: a randomized trial. Cutis 2001; 67 (6 Suppl.): 4-9
53. Ellis CN, Millikan LE, Smith EB, et al. Comparison of adapalene 0.1% solution and tretinoin 0.025% gel in the topical treatment of acne vulgaris. Br J Dermatol 1998; 139 Suppl. 52: 41-7
54. Grosshans E, Marks R, Mascaro JM, et al. Evaluation of clinical efficacy and safety of adapalene 0.1% gel versus tretinoin 0.025% gel in the treatment of acne vulgaris, with particular reference to the onset of action and impact on quality of life. Br J Dermatol 1998; 139 Suppl. 52: 26-33
55. Lucky AW, Cullen SI, Funicella T, et al. Double-blind, vehicle-controlled, multicenter comparison of two 0.025% tretinoin creams in patients with acne vulgaris. J Am Acad Dermatol 1998; 38 (4): S24-30
56. Lucky AW, Cullen SI, Jarratt MT, et al. Comparative efficacy and safety of two 0.025% tretinoin gels: results from a multicenter double-blind, parallel study. J Am Acad Dermatol 1998; 38 (4): S17-23
57. Cortes JE, Kantarjian H, O'Brien S, et al. All-trans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute promyelocytic leukemia. Cancer 1994; 73 (12): 2946-52
58. Fritsch PO, Honigsmann H, Jaschke E, et al. Augmentation of oral methoxsalen-photochemotherapy with an oral retinoic acid derivative. J Invest Dermatol 1978; 70 (4): 178-82
59. Stuttgen G, Ippen H, Mahrle G. Oral vitamin A acid in treatment of dermatoses with pathologic keratinization. Int J Dermatol 1977; 16 (6): 500-2
60. Lucek RW, Colburn WA. Clinical pharmacokinetics of the retinoids. Clin Pharmacokinet 1985; 10 (1): 38-62
61. Latriano L, Tzimas G, Wong F, et al. The percutaneous absorption of topically applied tretinoin and its effect on endogenous concentrations of tretinoin and its metabolites after single doses or long-term use. J Am Acad Dermatol 1997; 36 (3 Pt 2): S37-46
62. Van Hoogdalem EJ. Transdermal absorption of topical anti-acne agents in man; review of clinical pharmacokinetic data. J Eur Acad Dermatol Venereol 1998; II Suppl. 1: S13-9
63. Buchan P, Eckhoff C, Caron D, et al. Repeated topical administration of all-transretinoic acid and plasma levels of retinoic acids in humans. J Am Acad Dermatol 1994; 30 (3): 428-34
64. Clucas A, Verschoore M, Sorba V, et al. Adapalene 0.1% gel is better tolerated than tretinoin 0.025% gel in acne patients. J Am Acad Dermatol 1997; 36 (6 Pt 2): S116-8
65. Shibata K, Shimamoto Y, Ishibashi S, et al. Life-threatening hepatic toxicity caused by all-trans-retinoic acid in a patient with acute promyelocytic leukaemia. Clin Lab Haematol 1994; 16 (2): 191-5
66. Windhorst DB, Nigra T. General clinical toxicology of oral retinoids. J Am Acad Dermatol 1982; 6 (4 Pt 2 Suppl.): 675-82
67. Navarre-Belhassen C, Blanchet P, Hillaire-Buys D, et al. Multiple congenital malformations associated with topical tretinoin. Ann Pharmacother 1998; 32 (4): 505-6
68. Camera G, Pregliasco P. Ear malformation in baby born to mother using tretinoin cream [letter]. Lancet 1992; 339 (8794): 687
69. Lammer EJ, Chen DT, Hoar RM, et al. Retinoic acid embryopathy. N Engl J Med 1985; 313 (14): 837-41
70. Caron GA. Tretinoin and pregnancy [letter]. Lancet 1993; 341 (8861): 1664
71. Jick SS, Terris BZ, Jick H. First trimester topical tretinoin and congenital disorders. Lancet 1993; 341 (8854): 1181-2
72. Peck GL, Olsen TG, Yoder FW, et al. Prolonged remissions of cystic and conglobate acne with 13-cis-retinoic acid. N Engl J Med 1979; 300 (7): 329-33
73. Tang GW, Russell RM. 13-cis-retinoic acid is an endogenous compound in human serum. J Lipid Res 1990; 31 (2): 175-82
74. Peck GL. Retinoids in dermatology: an interim report. Arch Dermatol 1980; 116 (3): 283-4
75. Chalker DK, Lesher Jr JL, Smith Jr JG, et al. Efficacy of topical isotretinoin 0.05% gel in acne vulgaris: results of a multicenter, double-blind investigation. J Am Acad Dermatol 1987; 17 (2 Pt 1): 251-4
76. Langner A, Stapor W, Donald AE, et al. Double-blind, placebo-controlled study of the efficacy and safety of isotretinoin cream (0.05% w/w and 0.10% w/w) with sunscreens in the treatment of mild to moderate acne vulgaris. J Dermatolog Treat 2000; 11: 7-14
77. Cunliffe WJ, Glass D, Goode K, et al. A double-blind investigation of the potential systemic absorption of isotretinoin, when combined with chemical sunscreens, following topical application to patients with widespread acne of the face and trunk. Acta Derm Venereol 2001; 81 (1): 14-7
78. Chen C, Jensen BK, Mistry G, et al. Negligible systemic absorption of topical isotretinoin cream: implications for teratogenicity. J Clin Pharmacol 1997; 37 (4): 279-84
79. Brazzell RK, Colburn WA. Pharmacokinetics of the retinoids isotretinoin and etretinate: a comparative review. J Am Acad Dermatol 1982; 6 (4 Pt 2 Suppl.): 643-51
80. Reniers DE, Howard JM. Isotretinoin-induced inflammatory bowel disease in an adolescent. Ann Pharmacother 2001; 35 (10): 1214-6
81. Rappaport EB, Knapp M. Isotretinoin embryopathy: a continuing problem. J Clin Pharmacol 1989; 29 (5): 463-5
82. Benke PJ. The isotretinoin teratogen syndrome. JAMA 1984; 251 (24): 3267-9
83. Braun JT, Franciosi RA, Mastri AR, et al. Isotretinoin dysmorphic syndrome. Lancet 1984; I (8375): 506-7
84. Hersh JH, Danhauer DE, Hand ME, et al. Retinoic acid embryopathy: timing of exposure and effects on fetal development. JAMA 1985; 254 (7): 909-10
85. Roche Laboratories Inc. SMART guide to best practices: system to manage accutane related teratogenicity. Nutley (NJ): Roche Laboratories Inc, 2001
86. Bershad S, Rubinstein A, Paterniti JR, et al. Changes in plasma lipids and lipoproteins during isotretinoin therapy for acne. N Engl J Med 1985; 313 (16): 981-5
87. Roytman M, Frumkin A, Bohn TG. Pseudotumor cerebri caused by isotretinoin. Cutis 1988; 42 (5): 399-400
88. Tangrea JA, Kilcoyne RF, Taylor PR, et al. Skeletal hyperostosis in patients receiving chronic, very-low-dose isotretinoin. Arch Dermatol 1992; 128 (7): 921-5
89. Archer CB, Elias PM, Lowe NJ, et al. Extensive spinal hyperostosis in a patient receiving isotretinoin: progression after 4 years of etretinate therapy. Clin Exp Dermatol 1989; 14 (4): 319-21
90. McElwee NE, Schumacher MC, Johnson SC, et al. An observational study of isotretinoin recipients treated for acne in a health maintenance organization. Arch Dermatol 1991; 127 (3): 341-6
91. Marini JC, Hill S, Zasloff MA. Dense metaphyseal bands and growth arrest associated with isotretinoin therapy. Am J Dis Child 1988; 142 (3): 316-8
92. Martin P, Manley PN, Depew WT, et al. Isotretinoin-associated proctosigmoiditis. Gastroenterology 1987; 93 (3): 606-9
93. Wysowski DK, Pitts M, Beitz J. An analysis of reports of depression and suicide in patients treated with isotretinoin. J Am Acad Dermatol 2001; 45 (4): 515-9
94. Marsden JR. Effect of isotretinoin on carbamazepine pharmacokinetics. Br J Dermatol 1988; 119 (3): 403-4
95. Gottfried NS. Pseudo-tumor cerebri and acne [letter]. Mil Med 1991; 156 (8): A5
96. Cunliffe WJ, Caputo R, Dreno B, et al. Efficacy and safety comparison of adapalene (CD271) gel and tretinoin gel in the topical treatment of acne vulgaris: a European multicentre trial. J Dermatol Treatment 1997; 8: 173-8
97. Shalita A, Weiss JS, Chalker DK, et al. A comparison of the efficacy and safety of adapalene gel 0.1% and tretinoin gel 0.025% in the treatment of acne vulgaris: a multicenter trial. J Am Acad Dermatol 1996; 34 (3): 482-5
98. Shroot B. Pharmacodynamics and pharmacokinetics of topical adapalene. J Am Acad Dermatol 1998 Aug; 39 (2 Pt 3): S17-24
99. Allec J, Chatelus A, Wagner N. Skin distribution and pharmaceutical aspects of adapalene gel. J Am Acad Dermatol 1997; 36 (6 Pt 2): S119-25
100. Rolland A, Wagner N, Chatelus A, et al. Site-specific drug delivery to pilosebaceous structures using polymeric microspheres. Pharm Res 1993; 10 (12): 1738-44
101. Jamoulle JC, Grandjean L, Lamaud E, et al. Follicular penetration and distribution of topically applied CD 271, a new naphthoic acid derivative intended for topical acne treatment. J Invest Dermatol 1990; 94 (5): 731-2
102. Autret E, Berjot M, Jonville-Bera AP, et al. Anophthalmia and agenesis of optic chiasma associated with adapalene gel in early pregnancy [letter]. Lancet 1997; 350 (9074): 339
103. Chandrarama RA. Tazarotene: first of a new generation of receptor-selective retinoids. Br J Dermatol 1996; 135 Suppl. 49: 18-25
104. Leyden J, Lowe N, Kakita L, et al. Comparison of treatment of acne vulgaris with alternate-day applications of tazarotene 0.1% gel and once-daily applications of adapalene 0.1% gel: a randomized trial. Cutis 2001; 67 (6 Suppl.): 10-6
105. Shalita AR, Chalker DK, Griffith RF, et al. Tazarotene gel is safe and effective in the treatment of acne vulgaris: a multicenter, double-blind, vehicle-controlled study. Cutis 1999; 63 (6): 349-54
106. Chandraratna RA. Tazarotene: the first receptor-selective topical retinoid for the treatment of psoriasis. J Am Acad Dermatol 1997; 37 (2 Pt 3): S12-7
107. Duvic M. Pharmacologic profile of tazarotene. Cutis 1998; 61 (2 Suppl.): 22-6
108. Marks R. Early clinical development of tazarotene. Br J Dermatol 1996; 135 Suppl. 49: 26-31
109. Tang-Liu DD, Matsumoto RM, Usansky JI. Clinical pharmacokinetics and drug metabolism of tazarotene: a novel topical treatment for acne and psoriasis. Clin Pharmacokinet 1999; 37 (4): 273-87
110. Marks R. Pharmacokinetics and safety review of tazarotene. J Am Acad Dermatol 1998; 39 (4 Pt 2): S134-8
111. Menter A. Pharmacokinetics and safety of tazarotene. J Am Acad Dermatol 2000; 43 (2 Pt 3): S31-5
112. Kligman AM, Leyden JJ, Stewart R. New uses for benzoyl peroxide: a broad-spectrum antimicrobial agent. Int J Dermatol 1977; 16 (5): 413-7
113. Cunliffe WJ, Stainton C, Forster RA. Topical benzoyl peroxide increases the sebum excretion rate in patients with acne. Br J Dermatol 1983; 109 (5): 577-9
114. Nacht S, Gans EH, McGinley KJ, et al. Comparative activity of benzoyl peroxide and hexachlorophene: in vivo studies against propionibacterium acnes in humans. Arch Dermatol 1983; 119 (7): 577-9
115. Tucker SB, Tausend R, Cochran R, et al. Comparison of topical clindamycin phosphate, benzoyl peroxide, and a combination of the two for the treatment of acne vulgaris. Br J Dermatol 1984; 110 (4): 487-92
116. Swinyer LJ, Baker MD, Swinyer TA, et al. A comparative study of benzoyl peroxide and clindamycin phosphate for treating acne vulgaris. Br J Dermatol 1988; 119 (5): 615-22
117. Burke B, Eady EA, Cunliffe WJ. Benzoyl peroxide versus topical erythromycin in the treatment of acne vulgaris. Br J Dermatol 1983; 108 (2): 199-204
118. Chalker DK, Shalita A, Smith Jr JG, et al. A double-blind study of the effectiveness of a 3% erythromycin and 5% benzoyl peroxide combination in the treatment of acne vulgaris. J Am Acad Dermatol 1983; 9 (6): 933-6
119. Lookingbill DP, Chalker DK, Lindholm JS, et al. Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double-blind investigations. J Am Acad Dermatol 1997; 37 (4): 590-5
120. Eady EA, Bojar RA, Jones CE, et al. The effects of acne treatment with a combination of benzoyl peroxide and erythromycin on skin carriage of erythromycin-resistant propionibacteria. Br J Dermatol 1996; 134 (1): 107-13
121. Leyden JJ, McGinley KJ, Cavalieri S, et al. Propionibacterium acnes resistance to antibiotics in acne patients. J Am Acad Dermatol 1983; 8 (1): 41-5
122. Morelli R, Lanzarini M, Vincenzi C, et al. Contact dermatitis due to benzoyl peroxide. Contact Dermatitis 1989; 20 (3): 238-9
123. Zbinden G. Scientific opinion on the carcinogenic risk due to topical administration of benzoylperoxide for the treatment of acne vulgaris. Pharmacol Toxicol 1988; 63 (5): 307-9
124. Mandell GL, Bennet JE, Dolin R, eds. Principles and practice of infectious diseases. 5th ed. Philadelphia (PA): Churchill Livingstone, 2000: 394-7
125. Cambazard F. Clinical efficacy of Velac, a new tretinoin and clindamycin phosphate gel in acne vulgaris. J Eur Acad Dermatol Venereol 1998; 11 Suppl. 1: S20-7
126. Becker LE, Bergstresser PR, Whiting DA, et al. Topical clindamycin therapy for acne vulgaris: a cooperative clinical study. Arch Dermatol 1981; 117 (8): 482-5
127. Parker F. A comparison of clindamycin 1% solution versus clindamycin 1% gel in the treatment of acne vulgaris. Int J Dermatol 1987; 26 (2): 121-2
128. Goltz RW, Coryell GM, Schnieders JR, et al. A comparison of Cleocin T 1 percent solution and Cleocin T 1 percent lotion in the treatment of acne vulgaris. Cutis 1985; 36 (3): 265-8
129. Ellis CN, Leyden J, Katz HI, et al. Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis 200l; 67 (2 Suppl.): 13-20
130. Barza M, Goldstein JA, Kane A, et al. Systemic absorption of clindamycin hydrochloride after topical application. J Am Acad Dermatol 1982; 7 (2): 208-14
131. Stoughton RB, Cornell RC, Gange RW, et al. Double-blind comparison of topical 1 percent clindamycin phosphate (Cleocin T) and oral tetracycline 500 mg/day in the treatment of acne vulgaris. Cutis 1980; 26 (4): 424-5, 429
132. Thomsen RJ, Stranieri A, Knutson D, et al. Topical clindamycin treatment of acne: clinical, surface lipid composition, and quantitative surface microbiology response. Arch Dermatol 1980; 116 (9): 1031-4
133. Gordon RC, Regamey C, Kirby WM. Serum protein binding of erythromycin, lincomycin, and clindamycin. J Pharm Sci 1973; 62 (7): 1074-7
134. Bennett WM, Aronoff GR, Golper TA, et al. Drug prescribing in renal failure. 3rd ed. Philadelphia (PA): American College of Physicians, 1994
135. Fass RJ, Saslaw S. Clindamycin: clinical and laboratory evaluation of parenteral therapy. Am J Med Sci 1972; 263 (5): 368-82
136. DeHaan RM, Metzler CM, Schellenberg D, et al. Pharmacokinetic studies of clindamycin phosphate. J Clin Pharmacol 1973; 13 (5): 190-209
137. Fleming GF, Crowe GR. Granulocytopenia due to clindamycin [letter]. Med J Aust 1976; 1 (3): 70
138. Swenson RM, Michaelson TC, Daly MJ, et al. Clindamycin in infections of the female genital tract. Obstet Gynecol 1974; 44 (5): 699-702
139. Vikenes K, Lund-Tonnesen S, Schreiner A. Clostridium difficile-associated diarrhea after short term vaginal administration of clindamycin. Am J Gastroenterol 1999; 94 (7): 1969-70
140. Elmore M, Rissing JP, Rink L, et al. Clindamycin-associated hepatotoxicity. Am J Med 1974; 57 (4): 627-30
141. Poxton IR, McCoubrey J, Blair G. The pathogenicity of Clostridium difficile. Clin Microbiol Infect 2001; 7 (8): 421-7
142. Feingold DS, Chen WC, Chou DL, et al. Induction of colitis in hamsters by topical application of antibiotics. Arch Dermatol 1979; 115 (5): 580-1
143. Parry MF, Rha CK. Pseudomembranous colitis caused by topical clindamycin phosphate. Arch Dermatol 1986; 122 (5): 583-4
144. Milstone EB, McDonald AJ, Scholhamer Jr CF. Pseudomembranous colitis after topical application of clindamycin. Arch Dermatol 1981; 117 (3): 154-5
145. The transfer of drugs and other chemicals into human breast milk. Pediatrics 1983; 72 (3): 375-83
146. Al Ahdal O, Bevan DR. Clindamycin-induced neuromuscular blockade. Can J Anaesth 1995; 42 (7): 614-7
147. Igarashi K, Ishitsuka H, Kaji A. Comparative studies on the mechanism of action of lincomycin, streptomycin, and erythromycin. Biochem Biophys Res Commun 1969; 37 (3): 499-504
148. Pochi PE, Bagatell FK, Ellis CN, et al. Erythromycin 2 percent gel in the treatment of acne vulgaris. Cutis 1988; 41 (2): 132-6
149. Jones EL, Crumley AF. Topical erythromycin vs blank vehicle in a multiclinic acne study. Arch Dermatol 1981; 117 (9): 551-3
150. Puschmann M, Meyer-Rohn J. The efficacy of a topical preparation containing erythromycin in the treatment of acne. Dermatologica 1982; 164 (5): 343-9
151. Leyden JJ, Hickman JG, Jarratt MT, et al. The efficacy and safety of a combination benzoyl peroxide/clindamycin topical gel compared with benzoyl peroxide alone and a benzoyl peroxide/erythromycin combination product. J Cutan Med Surg 2001; 5 (1): 37-42
152. Schmidt JB, Knobler R, Neumann R, et al. [External erythromycin therapy of acne]. Z Hautkr 1983; 58 (24): 1754-60
153. Schmidt JB, Thurner J, Poitscheck C, et al. [Local acne therapy with erythromycin]. Z Hautkr 1982; 57 (2): 69-77
154. Zafrani ES, Ishak KG, Rudzki C. Cholestatic and hepatocellular injury associated with erythromycin esters: report of nine cases. Dig Dis Sci 1979; 24 (5): 385-96
155. Avila P, Capella D, Laporte JR, et al. Which salt of erythromycin is most hepatotoxic [letter]? Lancet 1988; I (8594): 1104
156. Haydon RC, Thelin JW, Davis WE. Erythromycin ototoxicity: analysis and conclusions based on 22 case reports. Otolaryngol Head Neck Surg 1984; 92 (6): 678-84
157. Jorro G, Morales C, Braso JV, et al. Anaphylaxis to erythromycin. Ann Allergy Asthma Immunol 1996; 77 (6): 456-8
158. Cooper WO, Griffin MR, Arbogast P, et al. Very early exposure to erythromycin and infantile hypertrophic pyloric stenosis. Arch Pediatr Adolesc Med 2002; 156 (7): 647-50
159. Gilman AG, Rall TW, Nies AS, et al., eds. Goodman and Gilman's the pharmacological basis of therapeutics. 8th ed. New York (NY): Pergamon Press, 1990
160. Olsen TG. Therapy of acne. Med Clin North Am 1982; 66 (4): 851-71
161. Hjorth N. Traditional topical treatment of acne. Acta Derm Venereol Suppl (Stockh) 1980; Suppl. 89: 53-6
162. Olin B, editor. Facts and comparisons. St Louis (Me): JB Lippincott Co, 1990
163. Schwarb FP, Gabard B, Rufli T, et al. Percutaneous absorption of salicylic acid in man after topical administration of three different formulations. Dermatology 1999; 198 (1): 44-51
164. Morra P, Bartle WR, Walker SE, et al. Serum concentrations of salicylic acid following topically applied salicylate derivatives. Ann Pharmacother 1996: 30 (9): 935-40
165. Pertoldi F, D'Orlando L, Mercante WP. [Acute salicylate intoxication after trancutaneous absorption]. Minerva Anestesiol 1999; 65 (7-8): 571-3
166. Candy JM, Morrison C, Paton RD, et al. Salicylate toxicity masquerading as malignant hyperthermia. Paediatr Anaesth 1998; 8 (5): 421-3
167. Germann R, Schindera I, Kuch M, et al. [Life threatening salicylate poisoning caused by percutaneous absorption in severe ichthyosis vulgaris]. Hautarzt 1996; 47 (8): 624-7
168. Chiaretti A, Schembri Wismayer D, Tortorolo L, et al. Salicylate intoxication using a skin ointment. Acta Paediatr 1997; 86 (3): 330-1
169. Poe TE, Scott RB, Keith Jr JF. Drug interactions with furosemide [letter]. J Fam Pract 1984; 18 (2): 204
170. Pec J, Strmenova M, Palencarova E, et al. Salicylate intoxication after use of topical salicylic acid ointment by a patient with psoriasis. Cutis 1992; 50 (4): 307-9
171. Davies MG, Briffa DV, Greaves MW. Systemic toxicity from topically applied salicylic acid. BMJ 1979; I (6164): 661
172. Cross SE, Anderson C, Thompson MJ, et al. Is there tissue penetration after application of topical salicylate formulations [letter]? Lancet 1997; 350 (9078): 636
173. Raschke R, Arnold-Capell PA, Richeson R, et al. Refractory hypoglycemia secondary to topical salicylate intoxication. Arch Intern Med 1991; 151 (3): 591-3
174. Yokoyama A, Takakubo F, Eto K, et al. Teratogenicity of aspirin and its metabolite, salicylic acid, in cultured rat embryos. Res Commun Chem Pathol Pharmacol 1984; 46 (1): 77-91
175. Lin AN, Reimer RJ, Carter DM. Sulfur revisited. J Am Acad Dermatol 1988; 18 (3): 553-8
176. Danto JL, Maddin WS, Stewart WD, et al. A controlled trial of benzoyl peroxide and precipitated sulfur cream in acne vulgaris. Appl Ther 1966; 8 (7): 624-5
177. Wilkinson RD, Adam JE, Murray JJ, et al. Benzoyl peroxide and sulfur: foundation for acne management. CMAJ 1966; 95 (1): 28-9
178. Breneman DL, Ariano MC. Successful treatment of acne vulgaris in women with a new topical sodium sulfacetamide/sulfur lotion. Int J Dermatol 1993; 32 (5): 365-7
179. Pandey J, Chellani H, Garg M, et al. Congenital sulfhemoglobin and transient methemoglobinemia secondary to diarrhoea. Indian J Pathol Microbiol 1996; 39 (3): 217-20
180. Blum JE, Coe FL. Metabolic acidosis after sulfur ingestion. N Engl J Med 1977; 297 (16): 869-70
181. Olansky S. Old drug - in a new system - revisited. Cutis 1977; 19 (6): 852-4
182. Genvert GI, Cohen EJ, Donnenfeld ED, et al. Erythema multiforme after use of topical sulfacetamide. Am J Ophthalmol 1985; 99 (4): 465-8
183. Rubin Z. Ophthalmic sulfonamide-induced Stevens-Johnson syndrome. Arch Dermatol 1977; 113 (2): 235-6
184. Gottschalk HR, Stone OJ, Stevens-Johnson syndrome from ophthalmic sulfonamide. Arch Dermatol 1976; 112 (4): 513-4
185. Spes CH, Angermann CE, Stempfle HU, et al. Sulfadiazine therapy for toxoplasmosis in heart transplant recipients decreases cyclosporine concentration. Clin Investig 1992; 70 (9): 752-4
186. Hansen JM, Kampmann JP, Siersbaek-Nielsen K, et al. The effect of different sulfonamides on phenytoin metabolism in man. Acta Med Scand Suppl 1979; 624: 106-10
187. Fitton A, Goa KL. Azelaic acid: a review of its pharmacological properties and therapeutic efficacy in acne and hyperpigmentary skin disorders. Drugs 1991; 41 (5): 780-98
188. Mackrides PS, Shaughnessy AF. Azelaic acid therapy for acne. Am Fam Physician 1996; 54 (8): 2457-9
189. Cunliffe WJ, Holland KT. Clinical and laboratory studies on treatment with 20% azelaic acid cream for acne. Acta Derm Venereol Suppl (Stockh) 1989; 143: 31-4
190. Hjorth N, Graupe K. Azelaic acid for the treatment of acne: a clinical comparison with oral tetracycline. Acta Derm Venereol Suppl (Stockh) 1989; 143: 45-8
191. Verallo-Rowell VM, Verallo V, Graupe K, et al. Double-blind comparison of azelaic acid and hydroquinone in the treatment of melasma. Acta Derm Venereol Suppl (Stockh) 1989; 143: 58-61
192. Katsambas A, Graupe K, Stratigos J. Clinical studies of 20% azelaic acid cream in the treatment of acne vulgaris: comparison with vehicle and topical tretinoin. Acta Derm Venereol Suppl (Stockh) 1989; 143: 35-9
193. Passi S, Nazzaro-Porro M, Picardo M, et al. Metabolism of straight saturated medium chain length (C9 to C12) dicarboxylic acids. J Lipid Res 1983; 24 (9): 1140-7
194. Willshaw HE, Rubinstein K. Azelaic acid in the treatment of ocular and adnexal malignant melanoma. Br J Ophthalmol 1983; 67 (1): 54-7